Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial

Abstract

Background Neutropenic sepsis remains a common treatment complication for patients receiving systemic anti-cancer treatment. The UK National Institute for Health and Care Excellence have not recommended switching from empirical intravenous antibiotics to oral antibiotics within 48 h for patients assessed as low risk for septic complications because of uncertainty about whether this would achieve comparable outcomes to using intravenous antibiotics for longer. The UK National Institute for Health Research funded the EASI-SWITCH trial to tackle this uncertainty. Methods The trial is a pragmatic, randomised, non-inferiority trial that aims to establish the clinical and cost-effectiveness of early switching from intravenous to oral antibiotics in cancer patients with low-risk neutropenic sepsis. Patients ≥ 16 years, receiving systemic anti-cancer treatment (acute leukaemics/stem cell transplants excluded), with a temperature of > 38 °C, neutrophil count ≤ 1.0 × 109/L, MASCC (Multinational Association of Supportive Care in Cancer) score ≥ 21 and receiving IV piperacillin/tazobactam or meropenem for less than 24 h are eligible to participate. Patients are randomised 1:1 either (i) to switch to oral ciprofloxacin and co-amoxiclav within 12–24 h of commencing intravenous antibiotics, completing at least 5 days total antibiotics (intervention), or (ii) to continue intravenous antibiotics for at least 48 h, with ongoing antibiotics being continued at the physician’s discretion (control). Patients are discharged home when their physician deems it appropriate. The primary outcome measure is a composite of treatment failures as assessed at day 14. The criteria for treatment failure include fever persistence or recurrence 72 h after starting intravenous antibiotics, escalation from protocolised antibiotics, hospital readmission related to infection/antibiotics, critical care support or death. Based on a 15% treatment failure rate in the control group and a 15% non-inferiority margin, the recruitment target is 230 patients. Discussion If the trial demonstrates non-inferiority of early switching to oral antibiotics, with potential benefits for patient quality of life and resource savings, this finding will have significant implications for the routine clinical management of those with low-risk neutropenic sepsis. Trial registration ISRCTN: 84288963. Registered on the 1 July 2015. 10.1186/ISRCTN84288963. EudraCT: 2015-002830-35.

Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT

“…Patients were randomised on a 1 : 1 basis to (1) early switch to oral ciprofloxacin (750 mg twice daily) and co-amoxiclav (625 mg three times daily) within 12-24 hours of starting antibiotics and completing 5 days treatment in total or to (2) continuation of i.v. antibiotics for at least 48 hours with ongoing treatment at physician discretion.…”

“…org/10.1186/s13063-020-04241-1. 1 Trial design EASI-SWITCH was a UK prospective Phase 3, randomised, open-label, non-inferiority trial to evaluate whether early switch to oral antibiotics is non-inferior to standard care in adult patients with cancer with NS at low risk of complications.…”

Securement to Prevent Noncuffed Central Venous Catheter Dislodgement in Pediatrics

“…An internal pilot study (n = 60) was embedded, and outcome pilot data were included within the main trial . The effectiveness trial progressed once the protocol was deemed feasible and after review by the data safety monitoring board on May 6, 2021. Data analysis was performed in January 2023.…”

Midline Compared With Peripheral Intravenous Catheters for Therapy of 4 Days or Longer in Pediatric Patients

“…A pilot study was embedded within the main trial, 26 with the effectiveness trial progressing once the protocol was deemed feasible 27 (after 66 participants: 86% recruitment, 0% attrition, 0% missing outcomes; no review of clinical outcome data) and after review by the Data Safety Monitoring Board on November 14, 2020.…”